BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 21215619)

  • 1. Acylideneoxoindoles: a new class of reversible inhibitors of human transglutaminase 2.
    Klöck C; Jin X; Choi K; Khosla C; Madrid PB; Spencer A; Raimundo BC; Boardman P; Lanza G; Griffin JH
    Bioorg Med Chem Lett; 2011 May; 21(9):2692-6. PubMed ID: 21215619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An unprecedented dual antagonist and agonist of human Transglutaminase 2.
    Yi MC; Palanski BA; Quintero SA; Plugis NM; Khosla C
    Bioorg Med Chem Lett; 2015 Nov; 25(21):4922-4926. PubMed ID: 26004580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cinnamoyl inhibitors of tissue transglutaminase.
    Pardin C; Pelletier JN; Lubell WD; Keillor JW
    J Org Chem; 2008 Aug; 73(15):5766-75. PubMed ID: 18582115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and evaluation of gluten peptide analogs as selective inhibitors of human tissue transglutaminase.
    Hausch F; Halttunen T; Mäki M; Khosla C
    Chem Biol; 2003 Mar; 10(3):225-31. PubMed ID: 12670536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversible and competitive cinnamoyl triazole inhibitors of tissue transglutaminase.
    Pardin C; Roy I; Lubell WD; Keillor JW
    Chem Biol Drug Des; 2008 Sep; 72(3):189-96. PubMed ID: 18715232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dihydroisoxazole analogs for labeling and visualization of catalytically active transglutaminase 2.
    Dafik L; Khosla C
    Chem Biol; 2011 Jan; 18(1):58-66. PubMed ID: 21276939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of transglutaminase 2 in celiac disease pathogenesis.
    Klöck C; Diraimondo TR; Khosla C
    Semin Immunopathol; 2012 Jul; 34(4):513-22. PubMed ID: 22437759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-activity relationship analysis of the selective inhibition of transglutaminase 2 by dihydroisoxazoles.
    Watts RE; Siegel M; Khosla C
    J Med Chem; 2006 Dec; 49(25):7493-501. PubMed ID: 17149878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Photolabeling of tissue transglutaminase reveals the binding mode of potent cinnamoyl inhibitors.
    Pardin C; Roy I; Chica RA; Bonneil E; Thibault P; Lubell WD; Pelletier JN; Keillor JW
    Biochemistry; 2009 Apr; 48(15):3346-53. PubMed ID: 19271761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent Progress in the Development of Transglutaminase 2 (TGase2) Inhibitors.
    Song M; Hwang H; Im CY; Kim SY
    J Med Chem; 2017 Jan; 60(2):554-567. PubMed ID: 28122456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of potent and specific dihydroisoxazole inhibitors of human transglutaminase 2.
    Klöck C; Herrera Z; Albertelli M; Khosla C
    J Med Chem; 2014 Nov; 57(21):9042-64. PubMed ID: 25333388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation and inhibition of transglutaminase 2 in mice.
    Dafik L; Albertelli M; Stamnaes J; Sollid LM; Khosla C
    PLoS One; 2012; 7(2):e30642. PubMed ID: 22319575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transglutaminase as a therapeutic target for celiac disease.
    Sulic AM; Kurppa K; Rauhavirta T; Kaukinen K; Lindfors K
    Expert Opin Ther Targets; 2015 Mar; 19(3):335-48. PubMed ID: 25410283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transglutaminase 2 undergoes a large conformational change upon activation.
    Pinkas DM; Strop P; Brunger AT; Khosla C
    PLoS Biol; 2007 Dec; 5(12):e327. PubMed ID: 18092889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2.
    Choi K; Siegel M; Piper JL; Yuan L; Cho E; Strnad P; Omary B; Rich KM; Khosla C
    Chem Biol; 2005 Apr; 12(4):469-75. PubMed ID: 15850984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of Potent and Selective Tissue Transglutaminase Inhibitors: Their Effect on TG2 Function and Application in Pathological Conditions.
    Badarau E; Wang Z; Rathbone DL; Costanzi A; Thibault T; Murdoch CE; El Alaoui S; Bartkeviciute M; Griffin M
    Chem Biol; 2015 Oct; 22(10):1347-61. PubMed ID: 26456735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of Transglutaminase 2 activity inhibitors in monocytes in vitro and their effect in a mouse model for multiple sclerosis.
    Chrobok NL; Bol JGJM; Jongenelen CA; Brevé JJP; El Alaoui S; Wilhelmus MMM; Drukarch B; van Dam AM
    PLoS One; 2018; 13(4):e0196433. PubMed ID: 29689097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transglutaminase 2 inhibitors and their therapeutic role in disease states.
    Siegel M; Khosla C
    Pharmacol Ther; 2007 Aug; 115(2):232-45. PubMed ID: 17582505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in the development of tissue transglutaminase (TG2) inhibitors.
    Badarau E; Collighan RJ; Griffin M
    Amino Acids; 2013 Jan; 44(1):119-27. PubMed ID: 22160259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated transglutaminase 2 activity is associated with hypoxia-induced experimental pulmonary hypertension in mice.
    DiRaimondo TR; Klöck C; Warburton R; Herrera Z; Penumatsa K; Toksoz D; Hill N; Khosla C; Fanburg B
    ACS Chem Biol; 2014 Jan; 9(1):266-75. PubMed ID: 24152195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.